A systematic review and meta-analysis of the impact of radiation-related lymphopenia on outcomes in pancreatic cancer
- PMID: 35132868
- DOI: 10.2217/fon-2021-0483
A systematic review and meta-analysis of the impact of radiation-related lymphopenia on outcomes in pancreatic cancer
Abstract
Background: Pancreatic cancer is a devastating disease with a 5-year survival rate of 5-10%. Radiation is commonly used in neoadjuvant and adjuvant settings to improve local control. Studies have shown that circulating lymphocyte count depletion after radiation has been associated with poor tumor control and inferior overall survival (OS) outcomes. Method: To better understand the impact of radiation-associated lymphopenia in pancreatic cancer, the authors undertook this systematic review and meta-analysis of clinical studies that have reported radiation-related lymphopenia in pancreatic cancer. Results: A systematic methodology search of PubMed, Embase and the Cochrane Library resulted in 2969 abstracts. Nine studies fulfilled the inclusion criteria. Six studies reported on outcomes in patients undergoing definitive chemoradiation and three studies comparing outcomes in stereotactic body radiotherapy versus definitive chemoradiation. The patients with severe lymphopenia were at increased risk of death with a pooled hazard ratio of 2.33 (95% CI: 1.79, 3.03; I2: 36%; p < 0.001) compared with patients with no severe lymphopenia. The odds of developing severe lymphopenia were 1.12 (95% CI: 0.45, 2.79; I2: 95%; p < 0.81). The pooled mean difference for OS was -6.80 months (95% CI: -10.35, -3.24; I2: 99%; p < 0.002), suggesting that patients who develop grade 3 or 4 lymphopenia have inferior median OS outcomes. Limiting the mean splenic dose to less than 9 Gy as well as various spleen dosimetric parameters such as visit (V)10 <32%, V15 <23% and V20 <15.4% can reduce the incidence of severe lymphopenia. Conclusion: Radiation-related lymphopenia is associated with an increased hazard of death and inferior median OS. Spleen dosimetric parameters correlate with the incidence of severe lymphopenia and with sub-optimal survival outcomes. There is a need to validate these findings in prospective studies.
Keywords: lymphopenia; mean splenic dose; pancreatic cancer; radiation.
Similar articles
-
Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):323-332. doi: 10.1016/j.ijrobp.2016.10.046. Epub 2016 Nov 8. Int J Radiat Oncol Biol Phys. 2017. PMID: 28068240
-
Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy.Radiat Oncol. 2021 Dec 24;16(1):242. doi: 10.1186/s13014-021-01969-1. Radiat Oncol. 2021. PMID: 34952610 Free PMC article.
-
A Systematic Review of Radiation-Related Lymphopenia in Genito-urinary Malignancies.Cancer Invest. 2021 Oct;39(9):769-776. doi: 10.1080/07357907.2021.1960992. Epub 2021 Aug 17. Cancer Invest. 2021. PMID: 34313522
-
A Systematic Review and Meta-analysis of the Impact of Radiation-Related Lymphopenia on Outcomes in High-Grade Gliomas.South Asian J Cancer. 2022 Aug 23;11(4):361-369. doi: 10.1055/s-0042-1753504. eCollection 2022 Oct. South Asian J Cancer. 2022. PMID: 36756098 Free PMC article.
-
Impact of radiotherapy parameters on the risk of lymphopenia in urological tumors: A systematic review of the literature.Radiother Oncol. 2022 May;170:64-69. doi: 10.1016/j.radonc.2022.02.030. Epub 2022 Mar 4. Radiother Oncol. 2022. PMID: 35257847
Cited by
-
Establishment of a prognostic nomogram for patients with locoregionally advanced nasopharyngeal carcinoma incorporating clinical characteristics and dynamic changes in hematological and inflammatory markers.Front Oncol. 2022 Oct 26;12:1032213. doi: 10.3389/fonc.2022.1032213. eCollection 2022. Front Oncol. 2022. PMID: 36387244 Free PMC article.
-
Normal tissue complication probability model for severe radiation-induced lymphopenia in patients with pancreatic cancer treated with concurrent chemoradiotherapy.Phys Imaging Radiat Oncol. 2024 Dec 22;33:100690. doi: 10.1016/j.phro.2024.100690. eCollection 2025 Jan. Phys Imaging Radiat Oncol. 2024. PMID: 39817285 Free PMC article.
-
Effects of radiotherapy on lymphocytes in patients with middle and lower esophageal cancer and its relationship with prognosis.World J Gastrointest Oncol. 2025 Jul 15;17(7):108205. doi: 10.4251/wjgo.v17.i7.108205. World J Gastrointest Oncol. 2025. PMID: 40697234 Free PMC article.
-
Proton beam therapy for esophageal cancer compared to existing treatments, including X-ray therapy and surgery.World J Gastrointest Surg. 2025 Jul 27;17(7):106767. doi: 10.4240/wjgs.v17.i7.106767. World J Gastrointest Surg. 2025. PMID: 40740933 Free PMC article. Review.
-
The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy.Front Immunol. 2024 Feb 8;15:1326757. doi: 10.3389/fimmu.2024.1326757. eCollection 2024. Front Immunol. 2024. PMID: 38390330 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical